Lucy Therapeutics Expands Leadership Team with Appointment of Julia Gaebler, Ph.D., as Chief Business Officer
Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.
- Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.
- Dr. Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, across biopharma, consulting, and academia.
- View the full release here: https://www.businesswire.com/news/home/20221115005644/en/
Dr. Gaebler will direct Lucy Therapeutics fundraising, growth and partnership activities for its promising proprietary preclinical compounds in Parkinsons disease, Rett syndrome, and other diseases of mitochondrial dysfunction. - Prior to joining Lucy Therapeutics, Dr. Gaebler was vice president of commercial strategy and portfolio planning at Milestone Pharmaceuticals and partner at Health Advances, a life-sciences strategy consulting firm.